NEW YORK (GenomeWeb) – Qiagen said this week that a judge has recommended partial dismissal of lawsuit filed against the company by Oxford Immunotec for patent infringement. The suit, filed in August 2015, concerns six patents and Qiagen's QuantiFERON Gold latent TB test. Oxford Immunotec alleged that Qiagen and other companies had infringed on its patents by developing their own TB tests. A magistrate judge has now recommended that part of the case against the defendants be dismissed as part of Oxford Immunotec's patents covered unpatentable subject matter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.